Michael F. Cola - 01 Oct 2021 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Chief Executive Officer, Director
Signature
/s/ Christopher R. Sullivan, by Power of Attorney
Issuer symbol
AVTX
Transactions as of
01 Oct 2021
Net transactions value
$0
Form type
4
Filing time
04 Oct 2021, 16:28:00 UTC
Previous filing
02 Jul 2021
Next filing
27 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTX Stock Option (Right to Buy) Award $0 +78,116 $0.000000 78,116 01 Oct 2021 Common Stock 78,116 $2.25 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 100% of this stock option will immediately vest on the date that it is granted. If employment is terminated prior to the end of the calendar quarter in which the option was granted, the number of shares underlying such stock option that reflects the percentage of calendar days remaining in such calendar quarter after such employment termination date shall be forfeited and deemed cancelled.